Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1, 1-dimethyl-ethylamino)-ethanone (LC15-0133) in rat liver microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 3, 2008, Pages 485-489

  Hye, Hyun Yoo ^a   Hye, Jin Chung ^a   Lee, Jaeick ^b   Lee, Chang Seok ^b   Min, Jung Kang ^a   Kim, Dong Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (5 TERT BUTYL [1,3,4]OXADIAZOLE 2 CARBONYL) 4 FLUORO PYRROLIDIN 1 YL] 2 (2 HYDROXY 1,1 DIMETHYL ETHYLAMINO) ETHANONE; DIPEPTIDYL PEPTIDASE IV; LC 15 0133; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; MASS SPECTROMETRY; METHYLATION; MICROSOMES, LIVER; OXADIAZOLES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 40849096097     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019133     Document Type: Article

References (13)

1. Ahren B and Schmitz O (2004) GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36:867-876.
2. Barnett A (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60:1454-1470.
3. Burke MD, Thompson S, Weaver RJ, Wolf CR, and Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936.
4. Campbell RK (2007) Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 41:51-60.
5. Coutts RT, Su P, and Baker GB (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 31:177-186.
6. Demuth HU, McIntosh CH, and Pederson RA (2005) Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33-44.
7. Ertl RP, Alworth WL, and Winston GW (1999) Liver microsomal cytochromes P450-dependent alkoxyphenoxazone O-dealkylation in vitro by alligator and rat: activities, inhibition, substrate preference, and discrimination factors. J Biochem Mol Toxicol 13:17-27.
8. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
9. Jurima-Romet M, Crawford K, Cyr T, and Inaba T (1994) Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
10. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, and Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
11. Pratley RE and Salsali A (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23:919-931.
12. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
13. Terhechte A and Blaschke G (1995) Investigation of the stereoselective metabolism of the chiral H1-antihistaminic drug terfenadine by high-performance liquid chromatography. J Chromatogr A 694:219-225.